2019 PharmSci 360
T cell engaging bispecific molecules (TCEs) are protein therapeutics that can bind to both T cells, via CD3 interactions, and target cells through target specific/overexpressed molecules. The endogenous, cytotoxic T cell response toward the target cells is facilitated by this TCE-induced bridging of the two cell types. Compared to a typical monoclonal antibody binding to its target, there are many specific considerations in modeling the interactions of a TCE to its dual-targets. In this short talk, we will discuss some of these differences in modeling TCE vs mAb binding and the potential impact on E-R relationship predictions.